Industry news that matters to you.  Learn more

OSI Pays Aveo $25M for Rights to Use Human Response Platform

The Astellas subsidiary OSI Pharmaceuticals will pay Aveo Pharmaceuticals $25 million to exercise its option to take on specific elements of the latter’s Human Response platform (HRP) technology in support of its own clinical development programs. The transferred technology will include components of the HRP platform for identifying and characterizing novel epithelial-mesenchymal transition (EMT) agents and patient-selection biomarkers.

Novel Biomarker May Predict Response to New VEGF Receptor Inhibitor

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO’s highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).